No retraction, correction or concern found when last checked on Oct 21, 2026.

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression

Brit Mollenhauer, Mohammed Dakna, Niels Kruse and 23 more

Movement Disorders · 2020 · CC BY

Abstract

Background:. The objective of this study was to assess neurofilament light chain as a Parkinson’s disease biomarker.

Methods:. We quantified neurofilament light chain in 2 independent cohorts: (1) longitudinal cerebrospinal fluid samples from the longitudinal de novo Parkinson’s disease cohort and (2) a large longitudinal cohort with serum samples from Parkinson’s disease, other cognate/neurodegenerative disorders, healthy controls, prodromal conditions, and mutation carriers.

Results:. In the Parkinson’s Progression Marker Initiative cohort, mean baseline serum neurofilament light chain was higher in Parkinson’s disease patients (13 ± 7.2 pg/mL) than in controls (12 ± 6.7 pg/mL), P = 0.0336. Serum neurofilament light chain increased longitudinally in Parkinson’s disease patients versus controls (P < 0.01). Motor scores were positively associated with neurofilament light chain, whereas some cognitive scores showed a negative association.

Conclusions:. Neurofilament light chain in serum samples is increased in Parkinson’s disease patients versus healthy controls, increases over time and with age, and correlates with clinical measures of Parkinson’s disease severity. Although the specificity of neurofilament light chain for Parkinson’s disease is low, it is the first blood-based biomarker candidate that could support disease stratification of Parkinson’s disease versus other cognate/neurodegenerative disorders, track clinical progression, and possibly assess responsiveness to neuroprotective treatments. However, use of neurofilament light chain as a biomarker of response to neuroprotective interventions remains to be assessed.

References 28

1.
Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861–870.
Not in our library10.1093/brain/awf080
2.
Adler CH, Beach TG, Hentz JG, Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014;83:406–412.
Not in our library10.1212/wnl.0000000000000641
3.
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases · 2013
No notice
4.
Bridel C, van Wieringen WN, Zetterberg H, Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurology 2019;76(9): 1035–1048.
Not in our library10.1001/jamaneurol.2019.1534
5.
Martinez MA, Olsson B, Bau L, Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler 2015;21:550–561.
Not in our library10.1177/1352458514549397
6.
Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with alzheimer disease. JAMA Neurology 2019;76(7):791–799.
Not in our library10.1001/jamaneurol.2019.0765
7.
Blood-based NfL · 2017
No notice
8.
Marques TM, van Rumund A, Oeckl P, Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 2019;92(13):e1479–e1486.
Not in our library10.1212/wnl.0000000000007179
9.
Backstrom DC, Eriksson Domellof M, Linder J, Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol 2015;72:1175–1182.
Not in our library10.1001/jamaneurol.2015.1449
10.
Lin CH, Li CH, Yang KC, Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 2019;93 (11):e1104–e1111.
Not in our library10.1212/wnl.0000000000008088
11.
Mollenhauer B, Trautmann E, Sixel-Doring F, Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 2013;81:1226–1234.
Not in our library10.1212/wnl.0b013e3182a6cbd5
12.
Mollenhauer B, Zimmermann J, Sixel-Doring F, Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 2016;87:168–177.
Not in our library10.1212/wnl.0000000000002651
13.
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease · 2017
No notice
14.
Goetz CG, Tilley BC, Shaftman SR, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–2170.
Not in our library10.1002/mds.22340
15.
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010;25:2649–2653.
Not in our library10.1002/mds.23429
16.
Chahine LM, Xie SX, Simuni T, Longitudinal changes in cognition in early Parkinson’s disease patients with REM sleep behavior disorder. Parkinsonism Relat Disord 2016;27:102–106.
Not in our library10.1016/j.parkreldis.2016.03.006
17.
Zetterberg H, Skillback T, Mattsson N, Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol 2016;73:60–67.
Not in our library10.1001/jamaneurol.2015.3037
18.
Miller AM, Rutkowska A, Bahl JM, Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. Bioanalysis 2016;8:2243–2254.
Not in our library10.4155/bio-2016-0114
19.
Shahim P, Tegner Y, Wilson DH, Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol 2014;71:684–692.
Not in our library10.1001/jamaneurol.2014.367
20.
Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010; 4:683–699.
Not in our library10.2217/bmm.10.90
21.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:298–300.
Not in our library
22.
Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 2019;0:1–12.
Not in our library10.1136/jnnp-2018-320106
23.
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197–211.
Not in our library10.1016/s0197-4580(02)00065-9
24.
Nixon RA, Shea TB. Dynamics of neuronal intermediate filaments: a developmental perspective. Cell Motil Cytoskeleton 1992;22: 81–91.
Not in our library10.1002/cm.970220202
25.
Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 2008;115:409–415.
Not in our library10.1007/s00401-008-0344-8
26.
Bateman RJ, Xiong C, Benzinger TL, Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012;367:795–804.
Not in our library10.1056/nejmoa1202753
27.
Benatar M, Wuu J, Lombardi V, Neurofilaments in presymptomatic ALS and the impact of genotype. Amyotroph ateral Scler Frontotemporal Degener 2019;20:538–548.
Not in our library10.1080/21678421.2019.1646769
28.
Mollenhauer B, Zimmermann J, Sixel-Doring F, Baseline predictors for progression 4 years after Parkinson’s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Disord 2019;34: 67–77.
Not in our library10.1002/mds.27492

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.